Teleflex Receives FDA Breakthrough Device Designation For Its Freesolve Resorbable Magnesium Scaffold For Percutaneous Coronary Intervention
To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threatening diseases or irreversibly debilitating diseases
Teleflex's new heart device got special FDA fast-track approval. This means the FDA thinks it could help sick patients in a new way.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.